

11 May 2023

Genflow Biosciences Plc

("Genflow" or "the Company")

Appointment and Internal Restructure

In light of the ongoing progress being achieved by Genflow, the Board of Directors has proactively decided to restructure both itself and the Company's Scientific Advisory Board ("SAB"). This step has been taken to align with the Company's current objectives and priorities in the US, including the OTCQB application previously announced, as outlined below:

- (a) **Tamara Joseph**, the Company's US-based Non-Executive Director, has been promoted to Chairperson of the Board. Her experience in financing, coupled with her familiarity with the US public markets, will play a crucial role going forward.

Tamara has an impressive track record in public and private financings, having supported Nasdaq financings in excess of \$800m. Her expertise in the field of finance is further strengthened by her academic credentials, which include a JD from the University of Michigan Law School and LLM degrees from the College of Europe in Belgium and the University of Paris.

Having served as an adviser to the boards of five US publicly traded biotechs, Tamara has demonstrated a strong ability to lead companies. Her promotion is a recognition of her expertise and strengthens the Company's links with the US market.

Yassine Bendiabdallah, will remain a key member of the Board and will continue to act as a Non-Executive Director.

- (b) **Vera Gorbunova PhD**, has been promoted to Chairperson of the SAB. Dr Gorbunova is an endowed Professor of Biology at the University of Rochester, New York, and Co-Director of the Rochester Ageing Research Center, where her research focuses on the mechanisms of longevity and genome stability, as well as studies on exceptionally long-lived mammals.

Throughout her career, Dr. Gorbunova has received numerous awards for her work, including from the Ellison Medical Foundation, the Glenn Foundation, the American Federation for Ageing Research, and the National Institutes of Health. Her research has also been recognized with the Cozzarelli Prize from PNAS, the prize for research on ageing from ADPS/Aliaz (France), the Prince Hitachi Prize in Comparative Oncology (Japan), and the Davey Prize from Wilmot Cancer Center.

As Chairperson of the SAB, Dr. Gorbunova's outstanding contributions to the field of longevity and her invaluable insights in this sector will be instrumental in guiding the Company's scientific research. This appointment is a testament to her expertise and achievements in the field.

Dr Eric Verdin will remain a key member of the SAB.

- (c) **Professor Dr Sven Francque** is joining the SAB. Professor Francque is a renowned expert in the field of nonalcoholic fatty liver disease (NAFLD) and its advanced form, nonalcoholic steatohepatitis (NASH).

He has a long-standing interest and expertise in NAFLD and NASH, with research focusing on the vascular changes in steatosis and their contribution to disease progression. Genflow stands to gain significant value from Professor Francque's extensive knowledge of NASH, particularly in identifying new targets and potential therapies for the disease.

Moreover, Professor Francque's expertise in clinical research and clinical trial design will be invaluable in the development of clinical trial programs for the Company's novel therapeutics. His membership on the SAB will play

development of clinical trial programs for the Company's novel therapeutics. His membership on the SNT will play a vital role in shaping and broadening the Company's strategy and direction, and his vast experience will be integral to achieving the Company's goal of improving the lives of patients with NAFLD and NASH.

Yassine Bendiabdallah, Director, commented: *"We remain dedicated to adapting and evolving in the ever-changing longevity space. Our collective and individual agility gives us a significant advantage over larger competitors and allows us to remain at the forefront of this dynamic industry."*

"I am incredibly proud of the strong team we have in place, and it's an honour to work alongside such esteemed leaders in this field. Our commitment to innovation and our ability to navigate the dynamic landscape of the longevity sector is central to our continued success."

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

For further information please contact:

Genflow Biosciences Plc	
Dr Eric Leire Chief Executive Officer	+32 477 495 881
Clear Capital Markets	
Corporate Broker Andrew Blaylock	+44 203 869 6080

About Genflow Biosciences

Genflow is a UK-based biotechnology company established in 2020. The Company is developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases. This will be done through novel therapeutics targeting aging in humans by using adeno-associated virus ("AAV") vectors to deliver copies of the Sirtuin-6 ("SIRT6") gene variant that is found in centenarians into cells.

Its mission is to increase our understanding of the factors that control and impact lifespan. Genflow researches, develops, and commercialises therapeutic solutions to lengthen health span, the amount of time we live in good health, creating biological interventions that enable longer and healthier lives. Genflow is dedicated to the development and commercialisation of novel therapeutics targeting aging in dogs and humans. By treating aging, Genflow can contribute to a decrease in healthcare costs and lessen the emotional and societal burden that comes with an aging population.

To learn more visit www.genflowbio.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCBBLFFXELBBBV